Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eva Reinke

Nurse Practitioner, Gerontology Pensacola, FL Nurse Practitioner

NPI 1780176578 CMS profile 10948903

435 Airport Blvd, Pensacola, FL 32503

Open in the dashboard

General payments

$8,455

454 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eva Reinke of Pensacola, FL is reported in the CMS Open Payments database as having received $8,455 across 454 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,455 116
2024 General $1,931 89
2023 General $1,377 74
2022 General $1,234 79
2021 General $1,458 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eva Reinke
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Eva Reinke were reported at $2,455. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Eva Reinke Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,458 $133 $44–$396 $132
2022 $1,234 $142 $48–$452 $149
2023 $1,377 $158 $53–$482 $160
2024 $1,931 $171 $55–$533 $164
2025 $2,455 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,618 99 payments
  2. AstraZeneca Pharmaceuticals LP $1,282 65 payments
  3. GlaxoSmithKline, LLC. $1,089 89 payments
  4. Genzyme Corporation $516 16 payments
  5. Regeneron Healthcare Solutions, Inc. $496 21 payments
  6. Jazz Pharmaceuticals Inc. $481 18 payments
  7. Actelion Pharmaceuticals US, Inc. $462 20 payments
  8. Insmed, Inc. $456 21 payments
  9. Grifols USA, LLC $268 12 payments
  10. Baxter Healthcare $251 8 payments
  11. Other $1,537 85 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,372 452 payments
  2. Education $84 2 payments
Products named General payments · program years 2021–2025
  1. OFEV $1,531 93 payments
  2. NUCALA $586 42 payments
  3. TEZSPIRE $577 27 payments
  4. DUPIXENT Immunology $516 16 payments
  5. TRELEGY ELLIPTA $503 47 payments
  6. XYWAV $464 17 payments
  7. Arikayce $456 21 payments
  8. FASENRA $424 14 payments
  9. OPSUMIT $414 18 payments
  10. DUPIXENT Inflammation And Immunology $390 17 payments
  11. Other $4,801 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,972

Median for Nurse Practitioner: 389

Drug cost

$995,122

Median for Nurse Practitioner: $21,885

Branded share of claims

76.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 313 $305,248
Ofev Nintedanib Esylate Brand 11 $143,638
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 105 $107,599
Breo Ellipta Fluticasone/Vilanterol Brand 191 $106,565
Tezspire Tezepelumab-Ekko Brand 15 $65,880
Dupixent Pen Dupilumab Brand 15 $65,217
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 58 $52,369
Symbicort Budesonide/Formoterol Fumarate Brand 50 $19,924
Spiriva Respimat Tiotropium Bromide Brand 13 $15,913
Advair Hfa Fluticasone Propion/Salmeterol Brand 29 $15,386

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$3,064

Medicare's payments for the services billed

Medicare patients

39

Average age 74

Services billed

39

17 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 67%
Arthritis 67%
Ischemic heart disease 44%
Atrial fibrillation 38%
Chronic kidney disease 38%
Diabetes 36%
Cancer 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $229
  • Regeneron Healthcare Solutions, Inc. $110
$339 15 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $243
$243 11 —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $233
$233 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $94
  • Amgen Inc. $84
$179 15 —
NUCALA
  • GlaxoSmithKline, LLC. $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

454 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record